Title |
Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
|
---|---|
Published in |
Clinical and Experimental Gastroenterology, July 2016
|
DOI | 10.2147/ceg.s91602 |
Pubmed ID | |
Authors |
Joseph Mermelstein, Alanna Chait Mermelstein, Maxwell M Chait |
Abstract |
Gastroesophageal reflux disease is the most common upper gastroenterology disorder in the US. It is associated with a variety of complications and significantly impacts quality of life. Proton pump inhibitors are the most effective treatment. Dexlansoprazole modified release (MR) is a proton pump inhibitor that employs a novel release formulation that prolongs its absorption and allows for more flexibility in dosing. Dexlansoprazole MR can be dosed without regard to food intake or time of day, and once-daily dosing may replace twice-daily dosing of other agents. Dexlansoprazole MR is effective for healing and maintenance of erosive esophagitis, and for the treatment of nonerosive disease, including nocturnal gastroesophageal reflux disease. Dexlansoprazole MR is safe and well tolerated, and can improve quality of life. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 40 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 13% |
Researcher | 5 | 13% |
Student > Bachelor | 4 | 10% |
Unspecified | 3 | 8% |
Student > Ph. D. Student | 3 | 8% |
Other | 6 | 15% |
Unknown | 14 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 33% |
Nursing and Health Professions | 3 | 8% |
Unspecified | 3 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Other | 4 | 10% |
Unknown | 14 | 35% |